Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Bristol-Myers' Skin Cancer Drug Gets FDA Nod


More than a dozen companies are testing similar immune-system therapies to fight cancer.

Bristol-Myers Squibb's (BMY) experimental drug ipilimumab for melanoma is the second treatment approved in a year that uses the body's immune system to fight cancer. But there are more than a dozen companies testing treatments in the late stages of human studies that aim to do the same thing.

The US Food and Drug Administration approved Bristol's drug today, giving an important spark to Bristol's pipeline of new treatments. (See Bristol-Myers Gains on Skin Cancer Treatment). The drug will be sold under the brand name Yervoy.

Dendreon's (DNDN) prostate cancer vaccine Provenge hit the market last year after the FDA gave it the OK. The treatment was a breakthrough for cancer therapies, helping patients to live longer without the many side effects of chemotherapy. Known as active immunotherapies, the treatments stimulate the immune system to attack cancer cells.

Bristol's treatment for advanced stages of skin cancer also is an active immunotherapy that's shown effectiveness in human trials. The drug does have some nasty side effects, including severe diarrhea, but it also is seen as an advance in cancer therapies.

Amgen (AMGN) just acquired closely held BioVex Group to gain a late-stage cancer vaccine, OncoVex, for melanoma and head and neck cancer. If the drug is approved and hits sales targets, the deal would be worth up to $1 billion.

Other companies developing skin cancer vaccines include GlaxoSmithKline (GSK), small-cap company Vical (VICL) and Pink Sheet company AVAX. (Each company is working separately.)

"Melanoma is a pretty crowded marketplace," says Michael Becker, senior partner at MB Becker Partners LLC.

Given the number of drug candidates, Becker sees at least three more US approvals of active immunotherapies in the next few years.

Several companies are testing vaccines for non-small cell lung cancer:Oncothyreon (ONTY) is working with Germany's Merck, French company Transgene is partnered with Novartis (NVS) and closely held Novarx is developing a therapy on its own.

Other companies conducting late-stage studies of cancer vaccines: Celldex Therapeutics (CLDX) is testing a therapy for brain cancer; Cel-Sci (CVM) is developing a head and neck product; Pink Sheet firm Biovest International is studying a non-Hodgkin lymphoma drug; Danish company Bavarian Nordic is developing a prostate cancer treatment; and UK-based Oxford BioMedica is testing the drug Trovax for kidney cancer.

Celldex was partnered with Pfizer (PFE) until last year when the pharmaceutical giant decided to scrap the program because it wasn't a big enough opportunity. (See Copying Dendreon). Becker says Pfizer's decision shouldn't be looked at as a signal that the Celldex treatment, rindopepimut, doesn't have potential. It just may not develop into a $1 billion drug, he says.

Lasting through April 15, 100% of the donations made to The Ruby Peck Foundation for Children's Education will be channeled to the children of Japan as they attempt to find their footing following this natural disaster; and to kick off this drive, we'll pledge $5000 to get it started. Please do what you can, as it will add up, and thanks.
< Previous
  • 1
Next >
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Featured Videos